Changting Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Changting Cui has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Bin Geng
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China
6 shared publications - Zhenzhen Chen
Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China (Z.C., H.Z., Q.Y., L.F., Q.L., X.G., F.Y., J. Cui, Y.T., J. Cai)
4 shared publications - Haizeng Zhang
Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China (Z.C., H.Z., Q.Y., L.F., Q.L., X.G., F.Y., J. Cui, Y.T., J. Cai)
3 shared publications - Guoheng Xu
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
2 shared publications Huimin Gao
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China
2 shared publications- Jun Cai
Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Chromobox 3 assembles an epigenetic complex contributing to cystathionine γ-lyase–mediated protection against aortic aneurysm/dissection
Hydrogen sulfide (H₂S), generated by cystathionine γ-lyase (CSE), protects against aortic aneurysm and dissection (AAD), yet its role in extracellular matrix (ECM) regulation remains unclear. Here, we demonstrate that CSE expression is markedly attenuated in vascular smooth muscle cells (VSMCs) from human AAD specimens and AngII-induced male murine models. VSMC-specific Cse deletion exacerbated AAD formation. Mechanistically, Cse deficiency downregulated CBX3, thereby relieving transcriptional repression of Adamts4. Cbx3 overexpression rescued the aggravated AAD phenotype in Cse-deficient male mice. We further identified a CBX3-centered epigenetic complex (SUV39H1, KDM2A, HDAC1, RING1) that coordinates H3K9/4 methylation and acetylation to regulate ECM remodeling, apoptosis and inflammation-related genes. Notably, CSE/H₂S induced CBX3 sulfhydration at C69, C160, and C177, enhancing protein stability by reducing ubiquitin-mediated degradation; Therapeutically, AAV-mediated Cse or Cbx3 delivery via an extravascular carrier attenuated AAD incidence and progression in male mice. Collectively, these findings define a VSMCs CSE/H₂S-CBX3 epigenetic axis that constrains AAD through regulation of the ADAMTS4-versican pathway.
- 4 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessChromobox 3 assembles an epigenetic complex contributing to cystathionine γ-lyase–mediated protection against aortic aneurysm/dissection
Hydrogen sulfide (H₂S), generated by cystathionine γ-lyase (CSE), protects against aortic aneurysm and dissection (AAD), yet its role in extracellular matrix (ECM) regulation remains unclear. Here, we demonstrate that CSE expression is markedly attenuated in vascular smooth muscle cells (VSMCs) from human AAD specimens and AngII-induced male murine models. VSMC-specific Cse deletion exacerbated AAD formation. Mechanistically, Cse deficiency downregulated CBX3, thereby relieving transcriptional repression of Adamts4. Cbx3 overexpression rescued the aggravated AAD phenotype in Cse-deficient male mice. We further identified a CBX3-centered epigenetic complex (SUV39H1, KDM2A, HDAC1, RING1) that coordinates H3K9/4 methylation and acetylation to regulate ECM remodeling, apoptosis and inflammation-related genes. Notably, CSE/H₂S induced CBX3 sulfhydration at C69, C160, and C177, enhancing protein stability by reducing ubiquitin-mediated degradation; Therapeutically, AAV-mediated Cse or Cbx3 delivery via an extravascular carrier attenuated AAD incidence and progression in male mice. Collectively, these findings define a VSMCs CSE/H₂S-CBX3 epigenetic axis that constrains AAD through regulation of the ADAMTS4-versican pathway.
- 28 April 2026
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 44 (16-18) , 859-877
Macrophage Ubiquitin-Activating Enzyme 1 Promotes Sepsis-Associated Acute Kidney Injury by Relieving Nucleoporin 35–Mediated Suppression of Nuclear Factor-κB Signaling
Aims: To determine the role of the ubiquitin-activating enzyme UBA1 in macrophage-mediated renal injury during sepsis-associated acute kidney injury (SA-AKI) and to elucidate the underlying molecular mechanism. Methods and Results: Using a cecal ligation and puncture mouse model, we evaluated renal function, inflammation, and survival in myeloid-specific Uba1 knockout mice ( Uba1 M-KO ) and littermate controls. Transcriptomic, proteomic, and ubiquitinome analyses were integrated with mechanistic studies in bone marrow–derived macrophages and renal tubular epithelial cell co-cultures. A pharmacologic UBA1 inhibitor (PYR-41) was tested for therapeutic efficacy. UBA1 expression was markedly increased in renal macrophages during SA-AKI. Uba1 M-KO mice demonstrated improved survival, preserved renal function, and attenuated inflammatory responses, as evidenced by reduced cytokine production, reactive oxygen species generation, apoptosis, and macrophage infiltration. Mechanistically, UBA1 promoted ubiquitination and degradation of the nuclear pore protein nucleoporin 35 (NUP35), impairing IκBα nuclear import and activating nuclear factor kappa B (NF-κB) signaling. This led to enhanced macrophage inflammatory activation and subsequent renal tubular injury. Pharmacologic inhibition of UBA1 recapitulated the protective effects of genetic deletion in vivo . Innovation and Conclusions: This study identifies UBA1-mediated NUP35 ubiquitination as a previously unrecognized checkpoint linking ubiquitin activation to nuclear pore integrity and inflammatory signaling in sepsis. UBA1 drives macrophage-mediated inflammation in SA-AKI by promoting NUP35 degradation and subsequent activation of NF-κB signaling. Targeting UBA1 represents a promising immunomodulatory strategy for the prevention and treatment of SA-AKI. Antioxid. Redox Signal. 44, 859–877.
- 28 April 2026
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 44 (16-18) , 859-877
Macrophage Ubiquitin-Activating Enzyme 1 Promotes Sepsis-Associated Acute Kidney Injury by Relieving Nucleoporin 35–Mediated Suppression of Nuclear Factor-κB Signaling
Aims: To determine the role of the ubiquitin-activating enzyme UBA1 in macrophage-mediated renal injury during sepsis-associated acute kidney injury (SA-AKI) and to elucidate the underlying molecular mechanism. Methods and Results: Using a cecal ligation and puncture mouse model, we evaluated renal function, inflammation, and survival in myeloid-specific Uba1 knockout mice ( Uba1 M-KO ) and littermate controls. Transcriptomic, proteomic, and ubiquitinome analyses were integrated with mechanistic studies in bone marrow–derived macrophages and renal tubular epithelial cell co-cultures. A pharmacologic UBA1 inhibitor (PYR-41) was tested for therapeutic efficacy. UBA1 expression was markedly increased in renal macrophages during SA-AKI. Uba1 M-KO mice demonstrated improved survival, preserved renal function, and attenuated inflammatory responses, as evidenced by reduced cytokine production, reactive oxygen species generation, apoptosis, and macrophage infiltration. Mechanistically, UBA1 promoted ubiquitination and degradation of the nuclear pore protein nucleoporin 35 (NUP35), impairing IκBα nuclear import and activating nuclear factor kappa B (NF-κB) signaling. This led to enhanced macrophage inflammatory activation and subsequent renal tubular injury. Pharmacologic inhibition of UBA1 recapitulated the protective effects of genetic deletion in vivo . Innovation and Conclusions: This study identifies UBA1-mediated NUP35 ubiquitination as a previously unrecognized checkpoint linking ubiquitin activation to nuclear pore integrity and inflammatory signaling in sepsis. UBA1 drives macrophage-mediated inflammation in SA-AKI by promoting NUP35 degradation and subsequent activation of NF-κB signaling. Targeting UBA1 represents a promising immunomodulatory strategy for the prevention and treatment of SA-AKI. Antioxid. Redox Signal. 44, 859–877.
- Open Access
- 3 September 2025
- Published by Springer Nature in Research Square
Chromobox 3 Assembles a Novel Epigenetic Complex Contributing to Cystathionine γ-lyase–mediated Protection Against Aortic Aneurysm/dissection
Hydrogen sulfide (H₂S), generated by cystathionine γ-lyase (CSE), exerts protective effects against aortic aneurysm/dissection (AAD). Proteoglycans, major extracellular matrix (ECM) components synthesized by vascular smooth muscle cells (VSMCs), preserve aortic wall integrity but also contribute to AAD pathogenesis. The mechanisms linking VSMC-derived CSE/H₂S to proteoglycan regulation in AAA remain undefined. Here, we identified reduced CSE expression in VSMCs (α-SMA⁺) from human AAD tissues and murine models. VSMC-specific CSE deletion (CSESMCKO) exacerbated AngII-induced AAD, with increased ADAMTS4 expression and versican degradation. Mechanistically, CSE loss suppressed CBX3, releasing Adamts4 transcriptional repression. Conversely, CBX3 overexpression ameliorated AAD in CSESMCKO mice. CBX3 formed an epigenetic complex with SUV39H1, KDM2A, HDAC1, and RING1, regulating H3K9/H3K4 methylation/acetylation, thereby modulating ECM remodeling, apoptosis, and inflammation. Therapeutically, AAV-mediated CSE or CBX3 delivery via extravascular carrier reduced AAD incidence and progression. Thus, VSMC-derived CSE/H₂S–CBX3 signaling restrains AAD through epigenetic regulation of the ADAMTS4–versican axis.
- 3 September 2025
- Published by Springer Nature in Research Square
Open AccessChromobox 3 Assembles a Novel Epigenetic Complex Contributing to Cystathionine γ-lyase–mediated Protection Against Aortic Aneurysm/dissection
Hydrogen sulfide (H₂S), generated by cystathionine γ-lyase (CSE), exerts protective effects against aortic aneurysm/dissection (AAD). Proteoglycans, major extracellular matrix (ECM) components synthesized by vascular smooth muscle cells (VSMCs), preserve aortic wall integrity but also contribute to AAD pathogenesis. The mechanisms linking VSMC-derived CSE/H₂S to proteoglycan regulation in AAA remain undefined. Here, we identified reduced CSE expression in VSMCs (α-SMA⁺) from human AAD tissues and murine models. VSMC-specific CSE deletion (CSESMCKO) exacerbated AngII-induced AAD, with increased ADAMTS4 expression and versican degradation. Mechanistically, CSE loss suppressed CBX3, releasing Adamts4 transcriptional repression. Conversely, CBX3 overexpression ameliorated AAD in CSESMCKO mice. CBX3 formed an epigenetic complex with SUV39H1, KDM2A, HDAC1, and RING1, regulating H3K9/H3K4 methylation/acetylation, thereby modulating ECM remodeling, apoptosis, and inflammation. Therapeutically, AAV-mediated CSE or CBX3 delivery via extravascular carrier reduced AAD incidence and progression. Thus, VSMC-derived CSE/H₂S–CBX3 signaling restrains AAD through epigenetic regulation of the ADAMTS4–versican axis.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (5) , 605-624
GPR146 Facilitates Blood Pressure Elevation and Vascular Remodeling via PIEZO1
BACKGROUND: Hypertension is a prevalent chronic disease worldwide. Elevated hydrostatic pressure (HP) is the main feature of hypertension. GPCRs (G-protein–coupled receptors) are crucial for vascular tone and a significant pharmacological target for drug development. Here, we aimed to identify the key GPCR under high HP, and explore its role and mechanism in hypertension and vascular remodeling. METHODS: First, RNA sequencing (RNA-seq) was performed under high HP and identified the highly expressed GPCR-GPR146. Furthermore, global knockout GPR146 mice, vascular smooth muscle cell (SMC)–specific knockin and knockout GPR146 mice were used to explore its function in hypertension. Next, an HP loading system ex vivo was established to evaluate the role of GPR146 in response to HP. Vascular SMC–specific Piezo1 (Piezo Type Mechanosensitive Ion Channel Component 1) mice were constructed to investigate the relationship between GPR146 and PIEZO1 . In vitro, GPR146-mediated downstream signaling transduction was detected by proximity ligation assay and bioluminescence resonance energy transfer. Finally, the therapeutic effect of hypertension was detected by GPR146 neutralization antibody injection. RESULTS: Under high HP, we identified a highly expressed GPCR-GPR146 in vascular SMCs by RNA-seq and confirmed it in the arterial media of patients with hypertension and animal models. Functionally, overexpression or deletion of Gpr146 in SMCs demonstrated that GPR146 facilitated vascular contraction, promoted vascular SMCs phenotype switching from a contractile phenotype to synthetic phenotype and proinflammation phenotype, and led to blood pressure elevation, vascular remodeling, and cardiac hypertrophy aggravation. In vitro, GPR146 was upregulated in an HP-dependent manner. Mechanistically, GPR146 is a Gα s -coupled GPCR activating the cAMP-CREB1 (cAMP response element–binding protein 1) signaling cascade. Notably, GPR146 upregulated PIEZO1 expression by enhancing CREB1 binding to the PIEZO1 promoter region. Piezo1 deletion in SMCs blocked Gpr146-induced blood pressure elevation and vascular dysfunction. GPR146 neutralization antibody injection markedly alleviates angiotensin II–induced hypertension and vascular remodeling. CONCLUSIONS: Collectively, GPR146 coupled with Gα s and activating the cAMP-CREB1-PIEZO1 signaling pathway contributes to hypertension and vascular remodeling. Blocking GPR146 is an effective therapeutic strategy for hypertension.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (5) , 605-624
GPR146 Facilitates Blood Pressure Elevation and Vascular Remodeling via PIEZO1
BACKGROUND: Hypertension is a prevalent chronic disease worldwide. Elevated hydrostatic pressure (HP) is the main feature of hypertension. GPCRs (G-protein–coupled receptors) are crucial for vascular tone and a significant pharmacological target for drug development. Here, we aimed to identify the key GPCR under high HP, and explore its role and mechanism in hypertension and vascular remodeling. METHODS: First, RNA sequencing (RNA-seq) was performed under high HP and identified the highly expressed GPCR-GPR146. Furthermore, global knockout GPR146 mice, vascular smooth muscle cell (SMC)–specific knockin and knockout GPR146 mice were used to explore its function in hypertension. Next, an HP loading system ex vivo was established to evaluate the role of GPR146 in response to HP. Vascular SMC–specific Piezo1 (Piezo Type Mechanosensitive Ion Channel Component 1) mice were constructed to investigate the relationship between GPR146 and PIEZO1 . In vitro, GPR146-mediated downstream signaling transduction was detected by proximity ligation assay and bioluminescence resonance energy transfer. Finally, the therapeutic effect of hypertension was detected by GPR146 neutralization antibody injection. RESULTS: Under high HP, we identified a highly expressed GPCR-GPR146 in vascular SMCs by RNA-seq and confirmed it in the arterial media of patients with hypertension and animal models. Functionally, overexpression or deletion of Gpr146 in SMCs demonstrated that GPR146 facilitated vascular contraction, promoted vascular SMCs phenotype switching from a contractile phenotype to synthetic phenotype and proinflammation phenotype, and led to blood pressure elevation, vascular remodeling, and cardiac hypertrophy aggravation. In vitro, GPR146 was upregulated in an HP-dependent manner. Mechanistically, GPR146 is a Gα s -coupled GPCR activating the cAMP-CREB1 (cAMP response element–binding protein 1) signaling cascade. Notably, GPR146 upregulated PIEZO1 expression by enhancing CREB1 binding to the PIEZO1 promoter region. Piezo1 deletion in SMCs blocked Gpr146-induced blood pressure elevation and vascular dysfunction. GPR146 neutralization antibody injection markedly alleviates angiotensin II–induced hypertension and vascular remodeling. CONCLUSIONS: Collectively, GPR146 coupled with Gα s and activating the cAMP-CREB1-PIEZO1 signaling pathway contributes to hypertension and vascular remodeling. Blocking GPR146 is an effective therapeutic strategy for hypertension.
- 28 January 2022
- Published by Taylor & Francis in Autophagy
- Vol. 18 (10) , 2270-2287
Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy
Vascular smooth muscle cells (VSMCs) contribute to plaque stability. VSMCs are also a major source of CTH (cystathionine gamma-lyase)-hydrogen sulfide (H2S), a protective gasotransmitter in atherosclerosis. However, the role of VSMC endogenous CTH-H2S in pathogenesis of plaque stability and the mechanism are unknown. In human carotid plaques, CTH expression in ACTA2+ cells was dramatically downregulated in lesion areas in comparison to non-lesion areas. Intraplaque CTH expression was positively correlated with collagen content, whereas there was a negative correlation with CD68+ and necrotic core area, resulting in a rigorous correlation with vulnerability index (r = −0.9033). Deletion of Cth in VSMCs exacerbated plaque vulnerability, and were associated with VSMC autophagy decline, all of which were rescued by H2S donor. In ox-LDL treated VSMCs, cth deletion reduced collagen and heightened apoptosis association with autophagy reduction, and vice versa. For the mechanism, CTH-H2S mediated VSMC autophagosome formation, autolysosome formation and lysosome function, in part by activation of TFEB, a master regulator for autophagy. Interference with TFEB blocked CTH-H2S effects on VSMCs collagen and apoptosis. Next, we demonstrated that CTH-H2S sulfhydrated TFEB at Cys212 site, facilitating its nuclear translocation, and then promoting transcription of its target genes such as ATG9A, LAPTM5 or LDLRAP1. Conclusively, CTH-H2S increases VSMC autophagy by sulfhydration and activation of TFEB, promotes collagen secretion and inhibits apoptosis, thereby attenuating atherogenesis and plaque vulnerability. CTH-H2S may act as a warning biomarker for vulnerable plaque. Abbreviations ATG9A: autophagy related 9A; CTH: cystathionine gamma-lyase; CQ: chloroquine; HASMCs: human aortic smooth muscle cells; H2S: hydrogen sulfide; LAMP1: lysosomal associated membrane protein 1; LAPTM5: lysosomal protein transmembrane 5; NaHS: sodium hydrosulfide hydrate; ox-LDL: oxidized-low density lipoprotein; PPG: DL- propagylglycine; TFEB: transcription factor EB; 3-MA: 3-methyladenine; VSMCs: vascular smooth muscle cells.
- 28 January 2022
- Published by Taylor & Francis in Autophagy
- Vol. 18 (10) , 2270-2287
Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy
Vascular smooth muscle cells (VSMCs) contribute to plaque stability. VSMCs are also a major source of CTH (cystathionine gamma-lyase)-hydrogen sulfide (H2S), a protective gasotransmitter in atherosclerosis. However, the role of VSMC endogenous CTH-H2S in pathogenesis of plaque stability and the mechanism are unknown. In human carotid plaques, CTH expression in ACTA2+ cells was dramatically downregulated in lesion areas in comparison to non-lesion areas. Intraplaque CTH expression was positively correlated with collagen content, whereas there was a negative correlation with CD68+ and necrotic core area, resulting in a rigorous correlation with vulnerability index (r = −0.9033). Deletion of Cth in VSMCs exacerbated plaque vulnerability, and were associated with VSMC autophagy decline, all of which were rescued by H2S donor. In ox-LDL treated VSMCs, cth deletion reduced collagen and heightened apoptosis association with autophagy reduction, and vice versa. For the mechanism, CTH-H2S mediated VSMC autophagosome formation, autolysosome formation and lysosome function, in part by activation of TFEB, a master regulator for autophagy. Interference with TFEB blocked CTH-H2S effects on VSMCs collagen and apoptosis. Next, we demonstrated that CTH-H2S sulfhydrated TFEB at Cys212 site, facilitating its nuclear translocation, and then promoting transcription of its target genes such as ATG9A, LAPTM5 or LDLRAP1. Conclusively, CTH-H2S increases VSMC autophagy by sulfhydration and activation of TFEB, promotes collagen secretion and inhibits apoptosis, thereby attenuating atherogenesis and plaque vulnerability. CTH-H2S may act as a warning biomarker for vulnerable plaque. Abbreviations ATG9A: autophagy related 9A; CTH: cystathionine gamma-lyase; CQ: chloroquine; HASMCs: human aortic smooth muscle cells; H2S: hydrogen sulfide; LAMP1: lysosomal associated membrane protein 1; LAPTM5: lysosomal protein transmembrane 5; NaHS: sodium hydrosulfide hydrate; ox-LDL: oxidized-low density lipoprotein; PPG: DL- propagylglycine; TFEB: transcription factor EB; 3-MA: 3-methyladenine; VSMCs: vascular smooth muscle cells.
- Open Access
- 29 August 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 236
Large-scale in silico identification of drugs exerting sex-specific effects in the heart
Major differences exist between men and women in both physiology and pathophysiology. Dissecting the underlying processes and contributing mechanisms of sex differences in health and disease represents a crucial step towards precision medicine. Considering the significant differences between men and women in the response to pharmacotherapies, our aim was to develop an in silico model able to predict sex-specific drug responses in a large-scale. For this purpose, we focused on cardiovascular effects because of their high morbidity and mortality. Our model predicted several drugs (including acebutolol and tacrine) with significant differences in the heart between men and women. To validate the sex-specific drug responses identified by our model, acebutolol was selected to lower blood pressure in spontaneous hypertensive rats (SHR), tacrine was used to assess cardiac injury in mice and metformin as control for a non-sex-specific response. As our model predicted, acebutolol exhibited a stronger decrease in heart rate and blood pressure in female than male SHRs. Tacrine lowered heart rate in male but not in female mice, induced higher plasma cTNI level and increased cardiac superoxide (DHE staining) generation in female than male mice, indicating stronger cardiac toxicity in female than male mice. To validate our model in humans, we employed two Chinese cohorts, which showed that among patients taking a beta-receptor blocker (metoprolol), women reached significantly lower diastolic blood pressure than men. We conclude that our in silico model could be translated into clinical practice to predict sex-specific drug responses, thereby contributing towards a more appropriate medical care for both men and women.
- 29 August 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 236
Open AccessLarge-scale in silico identification of drugs exerting sex-specific effects in the heart
Major differences exist between men and women in both physiology and pathophysiology. Dissecting the underlying processes and contributing mechanisms of sex differences in health and disease represents a crucial step towards precision medicine. Considering the significant differences between men and women in the response to pharmacotherapies, our aim was to develop an in silico model able to predict sex-specific drug responses in a large-scale. For this purpose, we focused on cardiovascular effects because of their high morbidity and mortality. Our model predicted several drugs (including acebutolol and tacrine) with significant differences in the heart between men and women. To validate the sex-specific drug responses identified by our model, acebutolol was selected to lower blood pressure in spontaneous hypertensive rats (SHR), tacrine was used to assess cardiac injury in mice and metformin as control for a non-sex-specific response. As our model predicted, acebutolol exhibited a stronger decrease in heart rate and blood pressure in female than male SHRs. Tacrine lowered heart rate in male but not in female mice, induced higher plasma cTNI level and increased cardiac superoxide (DHE staining) generation in female than male mice, indicating stronger cardiac toxicity in female than male mice. To validate our model in humans, we employed two Chinese cohorts, which showed that among patients taking a beta-receptor blocker (metoprolol), women reached significantly lower diastolic blood pressure than men. We conclude that our in silico model could be translated into clinical practice to predict sex-specific drug responses, thereby contributing towards a more appropriate medical care for both men and women.